If you are all set to move to Canada but have still not got approval from the CIC medical panel, all your effort and time invested in the entire application process can go to waste. So, to get a clean chit from the medical panel, one has to ensure that he is adopting a healthy routine and a balanced diet to avoid unforeseeable ailments.

One such ailment seen in most people is hypercholesterolemia or dyslipidemia. As the word suggests, it is the condition of high cholesterol level in the blood due to an unhealthy diet and may lead to coronary artery disease if left unattended. It also makes the individual more susceptible to the threat of heart stroke or attack. This is because, with the cholesterol level of blood rising at an alarming rate, it starts getting deposited on the walls of the blood vessels in the form of plaque.

The over deposition of plaque leads to thinning of the blood vessels and as a result, sufficient blood could not flow through these vessels. In addition to that, the presence of triglyceride in the blood can cause clotting leading to the formation of lumps in the blood, thus further reducing the rate of blood flow within the vessels. This ultimately makes the person prone to the risk of heart attack or heart stroke.

After analyzing the ill effects of excessive cholesterol level on your health, it’s time to ponder upon the question of why initially blood cholesterol level rises. Generally, high triglyceride or cholesterol levels are seen in people who are either alcohol addicts, overweight or suffering from diabetes. Ordinarily, the liver produces 80% of the cholesterol in the body, whereas the other 20% is obtained from dietary sources.

It is this 20% cholesterol which can be categorized into good cholesterol or HDL (High-Density Lipoprotein) and bad cholesterol or LDL (Low-Density Lipoprotein). Surprised to see that even cholesterol can be good or bad. Wait till you find out some more interesting facts about cholesterol and the regulations implemented by CIC medical panel to keep a tab on it.

High cholesterol level is an issue that requires immediate attention. Though everyone out there is equally prone to the risk of raised cholesterol levels in their blood, some people are more likely to get affected as compared to others. For instance, women who have reached the stage of menopause and are above 50 years of age are more likely to have increased cholesterol levels in the blood. Similarly, men in the age group of 40+ are more prone to the risk.

Apart from that, people who are overweight, or are smoking and alcohol addicts also face the danger of increased cholesterol level in blood. Also, people suffering from several diseases such as hypertension, diabetes, and coronary artery disease are more likely to have raised blood cholesterol levels. Therefore, while applying for a medical permit to visit Canada, these people should be especially cautious about the rules and regulations followed by the CIC medical panel.

A bioequivalence study is more important for the pharmaceutical industry to make sure that generic drugs are up to the quality and form their path to the market being well-timed. Across two-thirds of clinical research undertaken worldwide are to regulate bioequivalence. Hence, differences in the guidelines that govern such studies have huge ramifications on those working in the drug development field.

It is being accepted across the industry that a specific bioequivalence study should be involved earlier within the development process, but still, there is a shortage of guidance and information on how this can be acquired. The United States Food and Drugs Administration (FDA) just released new pharmaceutical industry counseling on the bioequivalence suggestions for specific products which report how the company will make information on how to plan specific bioequivalence studies available to public members.

Streamline Process

Formerly bodies who wanted to carry out bioequivalence studies need to contact the FDA for the particular guidance and wait for a reply which was time-consuming. In the instruction, the company said that putting this information on the internet will streamline the guidance method, making it more structured than the former process. General instruction on bioequivalence studies has been accessible to the pharmaceutical industry from the year 2000.

The difference will help pharmaceutical industrial members to fill out abbreviated new drug applications (ANDA), who are needed to prove that their product is bioequivalent to the reference listed drug. Although, the FDA also not be needed to publish information on a particular bioequivalence study before accepting ANDAs. In the modern years, the FDA has been focusing on streamlining the method for receiving generic drugs to market, publishing the Critical Path Chances for Generic Drugs in 2007.

The report detected many issues connected with bioequivalence studies involving the issues with bioequivalence studies for drugs that cannot be evaluated depending on blood plasma levels, such as nasal sprays, asthma inhalers and topical skin applications.

European Instruction for the Pharmaceutical Industry

Further instruction has also been problematic for pharmaceutical industries operating within Europe by the European Medicines Agency (EMEA). Particular guidelines connected with bioequivalence examination were issued in late January 2009 that made requirements for the conduct, design and assessment of such studies. Click on learn more to get more information. Although, the problem of creating bioequivalence studies for drugs that cannot be examined using generic blood plasma concentrations was not addressed.

The essential guidelines for the pharmaceutical industry addressed the nature and figure of test subjects, necessary doses, choice of the reference product and the standardization of the test conditions and the subjects. Below the instructions, there is a necessity for bio-analytical techniques to be verified and instruction for when cross-validation or incomplete validation could be used as a substitute to complete analytical validation.

Incomplete validation will be accepted when minute changes are made to an analytical process that has already been validated. This can involve the movement of the research to another laboratory or a change of appliance. Cross-validation will take place when data is acquired from separate research sites and should be carried out before the analysis process.